Arachidonic acid cytochrome P450 epoxygenase pathway

Journal of Lipid Research

Volumn 50, Issue SUPPL., 2009, Pages

  Spector, Arthur A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

2 epoxyeicosatrienoylglycerol; Dihydroxyeicosatrienoic acid; Eicosapentaenoic acid; Endocannabinoids; Epoxyeicosatrienoic acid; Fatty acid binding protein; Peroxisome proliferator activated receptor; Phospholipids; Soluble epoxide hydrolase

Indexed keywords

ARACHIDONATE EPOXYGENASE; CYTOCHROME P450; EPOXIDE HYDROLASE; ICOSANOID; PHOSPHOLIPID;

ANIMAL; CHEMISTRY; ENZYME ACTIVATION; METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; ENZYME ACTIVATION; EPOXIDE HYDROLASES; PHOSPHOLIPIDS; SIGNAL TRANSDUCTION;

EID: 66349109660     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R800038-JLR200     Document Type: Review

References (50)

1. Campbell, W. B., and D. R. Harder. 1999. Endothelium derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ. Res. 84: 484-488. (Pubitemid 29120015)
2. Capdevila, J. H., J. R. Falck, and R. C. Harris. 2000. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of arachidonic acid monooxygenases. J. Lipid Res. 41:163-181. (Pubitemid 30117856)
3. Roman, R. 2002. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82: 131-185. (Pubitemid 34654217)
4. Spector, A. A., and A. W. Norris. 2007. Action of epoxyeicosatrienoic acids on cellular function. Am. J. Physiol. Cell Physiol. 292: C996-C1012. (Pubitemid 46442641)
5. Campbell, W. B., and J. R. Falck. 2007. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension. 49:590-596.
6. Michaelis, U. R., and I. Fleming. 2006. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol. Ther. 111: 584-595. (Pubitemid 44160519)
7. Larsen, B. T., W. B. Campbell, and D. D. Gutterman. 2007. Beyond vasodilation: non-vascular roles for epoxyeicosatrienoic acids in the cardiovascular system. Trends Pharmacol. Sci. 28: 32-38. (Pubitemid 46038535)
8. Seubert, J. M., D. C. Zeldin, K. Nithipatikom, and G. J. Gross. 2007. Role of epoxyeicosatrienoic acids in protecting myocardium following ischemic/reperfusion injury. Prostagl. other LipidMediat. 82: 50-59.
9. Fleming, I. 2008. Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc. Med. 18: 20-25.
10. Imig, J. D. 2005. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Renal Physiol. 289: F496-F503. (Pubitemid 41208461)
11. Chiamvimonvat, N., C. M. Ho, H. J. Tsai, and B. D. Hammock. 2007. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J. Cardiovasc. Pharmacol. 50: 225-237. (Pubitemid 47428969)
12. Spector, A. A., X. Fang, G. D. Snyder, and N. L. Weintraub. 2004. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 43: 55-90. (Pubitemid 37433867)
13. Wang, Z., Y. Wei, J. R. Falck, K. R. Atcha, and W. H. Wang. 2008. Arachidonic acid inhibits K channels in the cortical collecting duct via cytochrome P-450 epoxygenase-dependent metabolic pathways. Am. J. Physiol. Renal Physiol. 294: F1441-F1447.
14. Widstrom, R. L., A.W. Norris, J. Van Der Veer, and A. A. Spector. 2003. Fatty acid binding proteins inhibit hydration of epoxyeicosatrienoic acids by soluble epoxide hydrolase. Biochemistry. 42: 11762-11767. (Pubitemid 37243637)
15. Fang, X., N. L. Weintraub, C. L. Oltman, L. L. Stoll, T. L. Kaduce, S. Harmon, K. C. Dellsperger, C. Morisseau, B. D. Hammock, and A. A. Spector. 2002. Human coronary endothelial cells convert 14,5-EET to a biologically active chain-shortened epoxide. Am. J. Physiol. Heart Circ. Physiol. 283: H2306-H2314. (Pubitemid 35345934)
16. Fang, X., T. L. Kaduce, N. L. Weintraub, S. Harmon, L. M. Teesch, K. C. Dellsperger, C. Morisseau, D. A. Thompson, B. D. Hammock, and A. A. Spector. 2001. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J. Biol. Chem. 276: 14867-14874.
17. Yi, X. Y., K. M. Gauthier, L. Cui, K. Nithipatikom, J. R. Falck, and W. B. Campbell. 2007. Metabolism of adrenic acid to vasodilatory 1α, 1β-dihomo-epoxyeicosatrienoic acids by bovine coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 292: H2265-H2274. (Pubitemid 47084607)
18. Larsen, B. T., D. D. Gutterman, A. Sato, A. Toyama, W. B. Campbell, D. C. Zeldin, V. L. Manthati, J. R. Falck, and H. Miura. 2008. Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors. Circ. Res. 102: 59-67.
19. Yang, W., V. R. Tuniki, S. Anjaiah, J. R. Falck, C. J. Hillard, and W. B. Campbell. 2008. Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20- 125I-14,15-epoxyeicosa- 8(Z)-enoic acid. J. Pharmacol. Exp. Ther. 324:1019-1027. (Pubitemid 351397827)
20. Liu, Y., Y. Zhang, K. Schmelzer, T. S. Lee, X. Fang, Y. Zhu, A. A. Spector, S. Gill, C. Morisseau, B. D. Hammock, et al. 2005. The anti-inflammatory effect of laminar flow: the role of PPARg, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci USA. 102: 16747-16752. (Pubitemid 41688848)
21. Chen, J. K., J. Chen, J. D. Imig, S. Wei, D. L. Hackey, J. S. Guthi, J. R. Falck, J. H. Capdevila, and R. C. Harris. 2008. Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. J. Biol. Chem. 283: 24511-24524.
22. Chen, J., J. K. Chen, J. R. Falck, J. S. Guthi, S. Anjaiah, J. H. Capdevila, and R. C. Harris. 2007. Mitogenic activity and signaling mechanism of 2-(14,15-epoxyeicosatrienoyl)glycerol, a novel cytochrome p450 arachidonate metabolite. Mol. Cell. Biol. 27: 3023-3034. (Pubitemid 46581315)
23. Snider, N. T., A. M. Kornilov, U. M. Kent, and P. F. Hollenberg. 2007. Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J. Pharmacol. Exp. Ther. 321: 590-597. (Pubitemid 46624513)
24. Carroll, M. A., A. B. Doumod, J. Li, M. K. Cheng, J. R. Falck, and J. C. McGiff. 2006. Adenosine 2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/ PKA pathway. Am. J. Physiol. Renal Physiol. 291: F155-F161. (Pubitemid 43945946)
25. Wang, X., C. L. Shen, M. T. Dyson, X. Yin, A. B. Schiffer, P. Grammas, and J. M. Stocco. 2006. The involvement of epoxygenase metabolites of arachidonic acid in cAMP-stimulated steroidogenesis and steroidogenic acute regulatory protein gene expression. J. Endocrinol. 190:871-878. (Pubitemid 44560260)
26. + channels. Microcirculation. 15: 137-150.
27. 2+ signaling and hyperpolarization in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 27: 2612-2618.
28. Spiecker, M., and J. K. Liao. 2005. Vascular protective effects of cytochrome P450 epoxygenase-derived eicosanoids. Arch. Biochem. Biophys. 433: 413-420. (Pubitemid 39592795)
29. Yang, S., L. Lin, J. X. Chen, C. R. Lee, J. M. Seubert, Y. Wang, H. Wang, Z. R. Chao, D. D. Tao, J. P. Gong, et al. 2007. Cytochrome P450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor alpha via MAPK and PI3K/Akt signaling pathway. Am. J. Physiol. Heart Circ. Physiol. 293: H142-H151. (Pubitemid 47105069)
30. Webber, A. C., R. Popp, U. Thomas Korff, R. Michaelis, C. Urbich, R. Busse, and I. Fleming. 2008. Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4. Arterioscler. Thronb. Vasc. Biol. 28:1123-1129.
31. Yan, G., S. Chen, B. You, and J. Sun. 2008. Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovasc. Res. 78: 308-314. (Pubitemid 351556100)
32. Zhang, B., H. Cao, and G. N. Rao. 2006. Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15-epoxyeicosatrienoic acid-induced angiogenesis. J. Biol. Chem. 281: 905-914.
33. Cheranov, S. Y., M. Karpurapu, D. Wang, B. Zhang, R. C. Venema, and G. N. Rao. 2008. An essential role for SRC-activated STAT-3 in 14,15-EET-induced VGEF expression and angiogenesis. Blood. 111:5581-5591.
34. Gross, G. J., K. M. Gauthier, J. Moore, J. R. Falck, B. D. Hammock, W. B. Campbell, and K. Nithipatikom. 2008. Effect of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in canine hearts. Am. J. Physiol. Heart Circ. Physiol. 294: H2838-H2844.
35. Wang, X. L., T. Lu, S. Cao, V. H. Shah, and H. C. Lee. 2006. Inhibition of ATP binding to the carboxyl terminus of Kir 6.2 by epoxyeicosatrienoic acids. Biochim. Biophys. Acta. 1761: 1041-1049. (Pubitemid 44354289)
36. Gross, G. J., A. Hsu, J. R. Falck, and K. Nithipatikom. 2007. Mechanism by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J. Mol. Cell. Cardiol. 42: 687-691. (Pubitemid 46349123)
37. Dhanasekaran, A., S. K. Gruenloh, J. N. Buonaccorsi, R. Zhang, G. R. Gross, J. R. Falck, P. K. Patel, E. R. Jacobs, and M. Medhora. 2008. Multiple antiapoptotic targets of PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am. J. Physiol. Heart Circ. Physiol. 294: H724-H735. (Pubitemid 351253284)
38. Shi, Y., X. Liu, D. Gebremedhin, J. R. Falck, D. R. Harder, and R. C. Koehler. 2008. Interaction of mechanisms involving epoxyeicosatrienoic acids, adenosine receptors, and metabotropic glutamate receptors in neurovascular coupling in rat whisker barrel cortex. J. Cereb. Blood Flow Metab. 28: 111-125.
39. Terashvili, M., L. F. Tseng, H. E. Wu, J. Narayanan, L. M. Hart, J. R. Falck, P. F. Pratt, and D. R. Harder. 2008. Antinociception produced by 14,15-epoxyeicosatrienoic acid is mediated by the activation of beta-endorphin and met-enkephalin in the rat ventrolateral periaqueductal gray matter. J. Pharmacol. Exp. Ther. 326: 614-622.
40. Zhang, W., I. P. Koerner, R. Noppens, M. Grafe, H. J. Tsai, C. Morisseau, A. Luria, B. D. Hammock, J. R. Falck, and N. J. Alkayed. 2007. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J. Cereb. Blood Flow Metab. 27: 1931-1940. (Pubitemid 350129162)
41. + channels in isolated rat coronary arterial myocytes. J. Physiol. 534: 651-667.
42. Fang, X., S. Hu, B. Xu, G. D. Snyder, S. Harmon, J. Tao, Y. Liu, B. Sangras, J. R. Falck, N. L. Weintraub, et al. 2006. 14,15- Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor a. Am. J. Physiol. Heart Circ. Physiol. 290: H55-H63.
43. Xu, D., N. Li, V. Timofeyev, L. Lu, H. J. Tsai, I. H. Kim, D. Tuteja, R. K. Mateo, A. Singapuri, B. B. Davis, et al. 2006. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci USA. 103: 18733-18738. (Pubitemid 44913479)
44. Ng, V. Y., C. Morisseau, J. R. Falck, B. D. Hammock, and D. L. Kroetz. 2006. Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor a-dependent repression of cyclin D1. Arterioscler. Thromb. Vasc. Biol. 26: 2462-2468. (Pubitemid 44607466)
45. Huang, H., C. Morisseau, J. Wang, T. Yang, J. R. Falck, B. D. Hammock, and M. H. Wang. 2007. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am. J. Physiol. Renal Physiol. 293: F342-F349. (Pubitemid 47345035)
46. Ai, D., Y. Fu, D. Guo, H. Tanaka, N. Wang, C. Tang, B. D. Hammock, J. Y. Shyy, and Y. Zhu. 2007. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelial cells in vitro and in vitro. Proc. Natl. Acad. Sci. USA. 104: 9018-9034.
47. Kim, I. H., H. J. Tsai, K. Nishi, T. Kasagami, C. Morisseau, and B. D. Hammock. 2007. 1,3-Disubstituted ureas functionalized with ether groups are potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties. J. Med. Chem. 50: 5217-5226. (Pubitemid 47585719)
48. Lauterbach, B., E. Barbosa-Siscard, M. H. Wang, H. Honeck, E. Kargel, J. Theuer, M. L. Schwartzman, H. Haller, F. C. Luft, M. Gollasch, et al. 2002. Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension. 39:609-613. (Pubitemid 34165192)
49. Hercule, H. C., B. Salanova, K. Essin, H. Honeck, J. R. Falck, M. Sausbier, P. Ruth, W. H. Schunk, F. C. Luft, and M. Gollasch. 2007. The vasodilator 17,18-epoxyeicosatetraenoic acid targets the poreforming BKα channel subunit in rodents. Exp. Physiol. 92: 1067-1076. (Pubitemid 47568840)
50. Ye, D., D. Zhang, C. Oltman, L. Dellsperger, H. C. Lee, and M. VanRollins. 2002. Cytochrome P-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J. Pharmacol. Exp. Ther. 303: 768-776. (Pubitemid 35231254)